StockData
Pyxis Oncology, Inc. logo

Pyxis Oncology, Inc. (PYXS) company profile

PYXSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30
$1.44+0.03 (+2.13%)

Close on Nov 17, 2026Market cap $120.11MP/E –Yield –

About Pyxis Oncology

Pharmaceutical Preparations, SIC 2834

Pyxis Oncology is a clinical-stage biopharmaceutical company that develops targeted cancer therapies for individuals with difficult-to-treat solid tumors. The company focuses primarily on treating recurrent and metastatic head and neck squamous cell carcinoma. Its lead investigational product candidate is micvotabart pelidotin, an antibody-drug conjugate designed to target an extracellular matrix protein variant within tumor microenvironments. The company evaluates this drug candidate both as a single-agent monotherapy and in combination with other cancer immunotherapies across various solid tumor types, including breast, cervical, and gastric cancers. It also maintains technology platforms for antibody discovery and conjugate design. The target population consists of cancer patients with advanced solid malignancies who require further intervention after initial systemic therapies.

The company conducts clinical development activities internationally, maintaining clinical trial sites across the United States, the European Union, and several other countries. Its operations are driven by a multidisciplinary workforce covering research, clinical development, and corporate administration. The provided text does not state the location of the company's headquarters.

Summary of the business section of Pyxis Oncology's latest annual report, written by StockData.

Company profile

Company

Legal name
Pyxis Oncology, Inc.
Founded
2018
Headquarters
Boston, MA
Address
321 Harrison Avenue 02118
Phone
(617) 221-9059
Employees
56, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Boston, Massachusetts

Stock & identifiers

Ticker
PYXS
Exchange
Nasdaq
IPO date
Oct 8, 2021
Shares outstanding
83M, Aug 12, 2026
Public float
$64.40M, Jun 30, 2025
Filer category
<br>Emerging growth company
SEC CIK
1782223
CUSIP
747324101
ISIN
US7473241013
FIGI
BBG00PQFFCV5
Share class FIGI
BBG00PQFFCW4
EIN
83-1160910

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Thomas CivikCEO & Chairman of the Board, Director221,886
Lara SullivanPresident ,CEO & CMO, Director2,403,882
Jitendra WadhanePrin Fin & Acct Officer512,882
Pamela Ann ConnealyCFO & COO3,425,179
Rachel HumphreyDirector81,309
Jakob DupontDirector73,741
Santhosh PalaniDirector6,000
Michael A. MetzgerDirector–
Freda C. Lewis-HallDirector241,405
John L. FlavinDirector413,015
Darren S. ClineDirector251,405

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Lara Sullivan
Former President, Chief Executive Officer and Chief Medical Officer
$646.88K–$723.08K$291.09K$10.50K$1.67M-76%
Jitendra Wadhane
Principal Financial and Accounting Officer
$414.00K–$207.70K$134.55K$10.50K$766.75K–
Pamela Connealy
Former Chief Financial Officer and Chief Operating Officer
$262.80K$402.37K$349.09K–$410.98K$1.43M-45%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 8, 2021
Offer price
$16.00
Securities offered
10,500,000
Gross proceeds
$168.00M
Exchange
Nasdaq
First trading day
Oct 8, 2021
First-day close
$13.20-17.5%
Lock-up ends (est.)
Apr 6, 2022

“The initial public offering price of our common stock is $16.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of March 20, 2026, we had 56 full-time permanent employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?